A fully automated oncoReveal® pan-cancer solid tumor assay for the characterization of EGFR and KRAS genes in formalin-fixed, paraffin-embedded (FFPE) tissues

Here we developed and evaluated an automated workflow for the oncoReveal® solid tumor assay on our Clear Dx™ platform with the aim of reducing the turnaround time for results, ease of performing a complex assay by less skilled technicians, as well as reducing the chances of human error. The results generated using automation are highly reproducible and comparable to the manual workflow and are for research evaluation only. The Clear Dx™ platform has the versatility to potentially automate any oncology NGS assay.